But the Galaxies Lung-201 trial features notable omissions, plus toxicity.

Efficacy with the group’s next-gen ALK and ROS1 inhibitors holds up, and first-line use could beckon.

The group’s B7-H3 ADC looks competitive versus rival projects from Merck/Daiichi and GSK/Hansoh.

The company’s HIF-2α inhibitor impresses on efficacy, but its long half life raises eyebrows.

Prelude’s SMARCA2 project and C4’s BRAF hopeful look lacklustre.

Backed by a slender survival signal the industry’s only anti-fucosyl-GM1 MAb is to go pivotal.

Niagara looks sound, but how much benefit did Imfinzi contribute to each of its two settings?

Moderna has also canned projects targeting KRAS and Ox40L/IL-23/IL-36γ.

Early data suggest that PD-(L)1 x VEGF bispecifics might challenge Keytruda in triple-negative disease.